Fluidigm Corporation (NASDAQ:FLDM) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, FLDM to report 3Q20 loss of $ 0.2 per share.
For the full year, analysts anticipate top line of $ 131.93 million, while looking forward to loss of $ 0.7 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 126.62 million ~ $ 130.14 million
Click Here For More Historical Outlooks Of Fluidigm Corporation
Previous Quarter Performance
Fluidigm Corporation outlined loss for the second quarter of $ 0.07 per share, from the revenue of $ 26.06 million. The quarterly revenues dropped 7.59 percent compared with the same quarter last year. Wall street analysts are predicting, FLDM to report 2Q20 loss of $ 0.23 per share from revenue of $ 19.07 million. The bottom line results beat street analysts by $ 0.16 or 69.57 percent, at the same time, top line results outshined analysts by $ 6.99 million or 36.65 percent.
Stock Performance
Shares of Fluidigm Corporation traded up $ 0.20 or 3.10 percent on Wednesday, reaching $ 6.66 with volume of 1.10 million shares. Fluidigm Corporation has traded high as $ 6.78 and has cracked $ 6.34 on the downward trend
The closing price of $ 6.66, representing a 452.14 % increase from the 52 week low of $ 1.17 and a 48.11 % decrease over the 52 week high of $ 12.45.
The company has a market capital of $ 491.48 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Fluidigm Corporation will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.fluidigm.com
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
